Navigation Links
Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
Date:12/11/2013

ANAHEIM, Calif., Dec. 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about January 24, 2014 to shareholders of record at the close of business on January 17, 2014.

The Company also announced today that it made open market purchases during the fourth quarter of 2013 of approximately 500,000 shares of Questcor common stock through December 10, 2013. The shares were purchased at an average price of $57.21 per share.

Through its repurchase program and its dividend, Questcor has returned approximately $440 million to shareholders since the beginning of 2008, representing approximately 60% of its operating cash flow over that same period.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indic
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
2. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
3. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
4. Questcor Honored as an "Everyday Hero" by NephCure Foundation
5. Questcor Adds G. Kelly Martin to Board of Directors
6. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
7. Questcor Reports Third Quarter Financial Results
8. Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
9. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
10. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
11. Questcor to Commence Phase 2 Study of Acthar for ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Cynosure, Inc. (NASDAQ: ... for non-invasive and minimally invasive applications, today announced that the ... Officer and Chief Financial Officer Timothy W. Baker ... 53, will continue to serve as CFO and will take ... remains Chairman and Chief Executive Officer. "Tim ...
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... , SALT LAKE CITY, Dec. 16 ... "Company"), a medical device company engaged in the development and ... that Joe Pepper, PhD, has been appointed to the TechniScan ... "Joe has extensive experience running small to large medical devices ...
... EVANSTON, Ill., Dec. 16 Naurex Inc., a new clinical ... disorders based on its novel GFPA NMDA receptor modulators, today ... of its lead compound GLYX-13 and has successfully dosed the ... functional partial agonist (GFPA) selective modulator of the NMDA receptor, ...
Cached Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... fuel cancer as well as evolutionary changes in a ... occur randomly throughout the genome. , However, recent studies ... of multiple mutations that arise simultaneously and in close ... are frequently found in regions where chromosomal rearrangements take ... Cell Reports , may one day lead to new ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is happy ... on July 30th. After months of planning, Dr. Hamilton ... state-of-the-art suite, located only steps away from the original ... one-on-one patient comfort, shorter wait times, and generally a ... new office-suite will continue to provide the same wide ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... -- Teenage girls who develop post-traumatic stress disorder after being ... research shows. In the study, researchers analyzed data collected ... part in a national telephone survey and were interviewed up ... time, 270 of the girls (15 percent) reported sexual victimization. ...
... Chicago College of Medicine have been awarded more than $11.7 ... The study, part of a multi-pronged investigation into acute ... Lung and Blood Institute, one of the National Institutes of ... acute respiratory distress syndrome, result from pulmonary edema -- leaky ...
... , FRIDAY, July 29 (HealthDay News) -- An ... -- a specific breed of dog known for truffle hunting, ... newly identified gene has enabled the development of a DNA ... for humans, providing new perspective on the development of a ...
... is available in Spanish . Patients suffering ... attacked and pursued, with the particularity that they express them ... Neurology has published the third consecutive work in five ... The first work showed in 2006 that 45% ...
... ethnic groups are more likely than others to store dangerous fat ... new study. This organ-hugging fat, which can lead to ... South Asia, the Canadian researchers reported in the July 28 online ... study showed South Asians have less space to store fat below ...
... bikers, brains, may also be contributing to hearing loss. ... out why. The distinctive roar of a Harley,s ... source of noise for motorcyclists is actually generated by ... speeds, the sound can exceed safe levels. Now, scientists ...
Cached Medicine News:Health News:Sexual Assault Doesn't Cause Binge Drinking in Girls: Study 2Health News:$12 million NIH grant to study acute lung injury 2Health News:New Dog Gene May Shed Light on Childhood Epilepsy 2Health News:REM sleep behavior disorder is a risk factor for Parkinson's disease 2Health News:Some Ethnic Groups More Vulnerable to Dangerous Fat 2
... K-ASSAY ASO / RF / ... to be used as a ... concentration for monitoring the performance ... Rheumatoid Factor (RF), and C-Reactive ...
... of benchtop microcentrifuges with the 5424. ... aerosol-tight rotor and a unique, contoured ... ,Model 5424 expands its application range ... microcentrifuge tubes, miniprep spin columns and ...
... hand, the Jarvik 2000 pump is about the ... titanium shell sits a direct-current motor, a rotor ... moving part: a small, spinning titanium impeller that ... 7 liters per minute. Rather than take over ...
... VentrAssist is a new third generation cardiac assist ... heart transplants for patients suffering heart failure., ,It ... left ventricle of the diseased heart to help ... restoring a better quality of life. , ,It ...
Medicine Products: